29.68
Bicara Therapeutics Inc Aktie (BCAX) Neueste Nachrichten
Bicara Therapeutics Inc stock hits all-time high at 29.92 USD - Investing.com Canada
Price to earnings forward of Bicara Therapeutics Inc. – NASDAQ:BCAX - TradingView
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Citizens upgrades Bicara Therapeutics stock price target on CRC data - Investing.com UK
Citizens upgrades Bicara Therapeutics stock price target on CRC data By Investing.com - Investing.com South Africa
BICARA THERAPEUTICS INC (BCAX) Stock Chart - ChartMill
Bicara Therapeutics stock hits 52-week high at 27.98 USD - Investing.com
Bicara Therapeutics stock hits 52-week high at 27.98 USD By Investing.com - Investing.com Australia
BCAXBicara Therapeutics Inc Volatility & Greeks - Finviz
Bicara Therapeutics Inc. Actuals & Estimates (BOATS:BCAX) - TradingView
Bicara Therapeutics Inc. Actuals & Estimates (NASDAQ:BCAX) - TradingView
Form 144 BICARA THERAPEUTICS INC. For: 25 June By Investing.com - Investing.com Nigeria
BCAX (NASDAQ: BCAX) affiliate to offer 50,000 shares after option exercise - Stock Titan
BCAX Forecast — Price Target — Prediction for 2027 - TradingView
Bicara Therapeutics Inc (BCAX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Bicara Therapeutics stock hits 52-week high at 24.29 USD - Investing.com
Bicara Therapeutics stock hits 52-week high at 24.29 USD By Investing.com - Investing.com South Africa
What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors? - AOL.com
Bicara Therapeutics Inc (BCAX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Bicara Therapeutics Inc (BCAX) Institutional Confidence - TradingKey
Bicara Therapeutics Inc (BCAX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Bicara Therapeutics Inc (BCAX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Bicara Therapeutics Inc (BCAX) Valuation: PE, PB & Fair Value Analysis - TradingKey
[Bicara Therapeutics (BCAX) Rises 1.35% as Stock Holds Above Key SupportTICK Divergence - Město Břeclav
Bicara Therapeutics Inc (BCAX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Bicara Therapeutics Inc (BCAX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bicara Therapeutics Inc (BCAX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Bicara Therapeutics Inc. appoints Chris Sarchi as Chief Commercial Officer to drive commercial growth - Traders Union
Bicara Therapeutics CEO Sells 15,000 Shares: Insider Transaction Under ScrutinyDividend Earnings Report - newsline.com
What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors? - The Motley Fool
Bicara Therapeutics Inc. joins ACS CAN in efforts to shape evidence-based cancer policies - Traders Union
Bicara Therapeutics Holds 2026 Annual Stockholder Meeting - TipRanks
[Form 4] Bicara Therapeutics Inc. Insider Trading Activity - Stock Titan
Bicara Therapeutics (BCAX) director receives 19,475-share option tied to RA Capital - Stock Titan
[8-K] Bicara Therapeutics Inc. Reports Material Event - Stock Titan
Bicara Therapeutics Inc. presents three year Phase 1b results for ficerafusp alfa combination in HPV negative HNSCC - Traders Union
BCAX Q1 2026 Earnings: Wider-than-Expected Loss Amid Pre-Clinical Pipeline ProgressDebt Analysis Report - newsline.com
Bicara Therapeutics (BCAX) Edges Lower, Tests Key Support LevelsCumulative Volume - newsline.com
BCAX Q1 2026 Earnings: Wider-Than-Expected Loss Highlights Pre‑Revenue Biotech’s R&D SpendingFinancial Data - newsline.com
Analysts’ Top Healthcare Picks: Vertex Pharmaceuticals (VRTX), Bicara Therapeutics Inc. (BCAX) - The Globe and Mail
Cantor Fitzgerald reiterates Bicara Therapeutics stock rating - Investing.com
Cantor Fitzgerald reiterates Bicara Therapeutics stock rating By Investing.com - Investing.com India
Bicara (BCAX) Q4 2025 Earnings Transcript - AOL.com
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):